Clinical Trial

Entera Bio to Participate in Upcoming Events

JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the…

10 months ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric CancersNEW…

10 months ago

CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab

VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab,…

10 months ago

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Tobin “Toby” Schilke…

10 months ago

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today…

10 months ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and…

10 months ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in…

10 months ago

Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 24, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to…

10 months ago

Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel Disease at ECCO 2025

MORRIS PLAINS, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ensho Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on…

10 months ago

Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration

ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BIOX) ("Biostax" or "the Company"), a biopharmaceutical company…

10 months ago